Drug-induced phospholipidosis: Are there functional consequences?

Experimental Biology and Medicine

Volumn 226, Issue 9, 2001, Pages 825-830

  Reasor, Mark J ^a   Kacew, Sam ^b  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Alveolar macrophages; Amiodarone; Cationic amphiphilic drugs; Lysosomes; Mice; Phagocytosis; Phospholipase; Phospholipidosis; Rats

Indexed keywords

AMIODARONE; AMPHOPHILE; CATION; CHLORCYCLIZINE; FLUOXETINE; GENTAMICIN; IMIPRAMINE; NEW DRUG; PHOSPHOLIPASE; PHOSPHOLIPID; TAMOXIFEN;

CELL ULTRASTRUCTURE; DRUG INDUSTRY; DRUG SCREENING; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; LAMELLAR BODY; LIPID STORAGE; LIPIDOSIS; LIPOPHILICITY; PATHOGENESIS; PHOSPHOLIPID METABOLISM; SHORT SURVEY; STRUCTURE ACTIVITY RELATION;

ANIMALIA;

EID: 0035687129     PISSN: 00379727     EISSN: None     Source Type: Journal    
DOI: 10.1177/153537020122600903     Document Type: Short Survey

References (71)

1. Drug-induced lysosomal storage disorders
2. Cationic amphiphilic drugs
3. Cationic amphiphilic drugs and phospholipid storage disorder
4. Lysosomal alterations in cultured macrophages exposed to anorexigenic and psychotropic drugs
5. Lipidosis-like alterations in cultured macrophages exposed to local anaesthetics
6. Changes in saccharide and phospholipid content associated with drug storage in cultured rabbit aorta muscle cells
7. In vivo and in vitro reversibility of chlorphentermine-induced phospholipidosis in rat alveolar macrophages
8. Effect of chlorphentermine on the lipids of rat lungs
9. Drug-induced foam cell reactions in rats. II. Chemical analysis of lipids stored in lungs and foam cells after treatment with chlorphentermine, 5-[p-(fluoren-9-ylidenemethyl)phenyl]-2-piperidineethanol(RMI 10.393) and 1-chloramitriptyline
10. Chlorphentermine-induced alterations in pulmonary phospholipid content in rats
11. Amiodarone pulmonary toxicity: Biochemical evidence for a cellular phospholipidosis in the bronchoalveolar lavage fluid of human subjects
12. Amiodarone-induced pulmonary toxicity in rats: Biochemical and pharmacological characteristics
13. Drug-induced phospholipidosis. II. Alterations in the phospholipid pattern of organs from mice, rats and guinea pigs after chronic treatment with chlorphentermine
14. Drug-induced lipidosis and the alveolar macrophage
15. Phospholipidosis in the alveolar macrophage induced by cationic amphiphilic drugs
16. Role of the alveolar macrophage in the induction of pulmonary phospholipidosis: Pharmacologic and toxicologic considerations
17. A review of the biology and toxicological implications of the induction of lysosomal lamellar bodies by drugs
18. Molecular studies of the induction of cellular phospholipidosis by cationic amphiphilic drugs
19. Pulmonary and generalized lysosomal storage induced by amphiphilic drugs
20. Role of age in amphiphilic drug-induced pulmonary morphological and metabolic responses
21. Newborn response to cationic amphiphilic drugs
22. Human accumulation potential of xenobiotics: Potential of catamphiphilic drugs to promote their accumulation via inducing lipidosis or mucopolysaccharidosis
23. Alveolar proteinosis and phospholipidoses of the lungs
24. Perspectives on intracellular storage and transport of cationic-lipophilic drugs
25. Cationic amphiphilic drug-induced phospholipidosis
26. Antidepressant-induced lipidosis with special reference to tricyclic compounds
27. Chloroquine: Pathological changes observed in rats which for two years had been fed various proportions
28. The occurrence of huge cells in pulmonary alveoli of rats treated by an anorexic drug
29. Histopatholic analysis of suspected amiodarone hepatotoxicity
30. Perhexiline maleate-induced cirrhosis
31. Fluoxetine hydrochloride-(Prozac) induced pulmonary disease
32. Experimental studies on nephrotoxicity of aminoglycosides at low doses: Mechanisms and perspectives
33. Drug-induced generalized phospholipidosis
34. Chlorphentermine-induced lipidosis-like ultrastructural alterations in lungs and adrenal glands of several species
35. Alterations in newborn and adult rat lung morphology and phospholipid levels after chlorcyclizine or chlorphentermine treatment
36. Amiodarone-induced phospholipidosis in rat alveolar macrophages
37. Strain as a determinant factor in the differential responsiveness of rats to chemicals
38. Role of rat strain in differential sensitivity to pharmaceutical agents and naturally occurring substances
39. Lipidosis induced by amphiphilic cationic drugs
40. Comparative evaluation of amiodarone-induced phospholipidosis and drug accumulation in Fischer-344 and Sprague-Dawley rats
41. Mechanism of cationic amphiphilic drug inhibition of purified lysosomal phospholipase A1
42. Fluorescence studies of the binding of amphiphilic amines with phospholipids
43. Effect of cationic amphiphilic drugs on the hydrolysis of acidic and neutral phospholipids by liver lysosomal phospholipase A
44. Biochemical and morphologic investigation of the influence of chlorphentermine and subsequent withdrawal on newborn rat lung
45. Recovery from chlorphentermine-induced phospholipidosis in rat alveolar macrophages. I. Biochemical and cellular features
46. Recovery from chlorphentermine-induced phospholipidosis in rat alveolar macrophages. II. Morphological features
47. Amiodarone-induced cornea verticillata
48. Neuopathy and fatal hepatitis in a patient receiving amiodarone
49. Amiodarone hepatotoxicity simulating alcoholic liver disease
50. Chloroquine-induced phospholipid fatty liver
51. Effects of amiodarone-induced phospholipidosis on pulmonary host defense functions in rats
52. Alveolar macrophage mediated pulmonary clearance suppressed by drug-induced phospholipidosis
53. Amiodarone-induced cytoplasmic lamellar body formation in cultured primary rat and human hepatocytes: Relationship to cell function and cytotoxicity
54. Role of oxidative stress in amiodarone-induced toxicity
55. Amiodarone causes decreased cell-mediated immune responses and inhibits the phospholipase C signaling pathway
56. Morphological and functional changes in mouse splenic lymphocytes following in vivo and in vitro exposure to chlorphentermine
57. Tricyclic antidepressants inhibit IL-6, IL-1β and TNF-α release in human blood monocytes and IL-2 and interferon-γ in T cells
58. Disobutamide: A model agent for investigating intracellular drug storage
59. Lens opacities associated with lipidosis-like ultrastructural alterations in rats treated with chloroquine, chlorphentermine, or iprindole
60. Keratopathy after oral adminstration of tilorone hydrochloride
61. Amiodarone keratopathy: Drug-induced lipid storage disease
62. Acute silica toxicity: Attenuation by amiodarone-induced pulmonary phospholipidosis
63. Subchronic pulmonary inflammation and fibrosis induced by silica in rates are attenuated by amiodarone
64. The effect of chlorphentermine pretreatment on the toxicity of nitrogen dioxide
65. Aminoglycoside nephrotoxicity
66. Cationic amphiphilic drug-induced renal cortical lyososomal phospholipidosis: An in vivo comparative study with gentamicin and chlorphentermine
67. Pathogenic factors in aminoglycoside-induced nephrotoxicity
68. Aminoglycoside-induced renal phospholipidosis and nephrotoxicity
69. Comparative assessment of poly-L-aspartic and poly-L-glutamic acids as protectants against gentamicin-induced renal lysosomal phospholipidosis, phospholipiduria and cell proliferation in rats
70. Inhibition of gentamicin-induced nephrotoxicity by lithium in rat
71. Gentamicin nephrotoxicity in humans and animals: Some recent research